Pungolino, E., Rossi, G., Angela Mura, M., Perego, A., Maria Orlandi, E., Turrini, M., et al. (2015). REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data. Intervento presentato a: 57th Annual Meeting of the American-Society-of-Hematology - DEC 05-08, 2015, Orlando, FL [10.1182/blood.V126.23.1597.1597].

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Roberto Cairoli
2015

paper
hematology
English
57th Annual Meeting of the American-Society-of-Hematology - DEC 05-08, 2015
2015
2015
126
23
1597
none
Pungolino, E., Rossi, G., Angela Mura, M., Perego, A., Maria Orlandi, E., Turrini, M., et al. (2015). REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data. Intervento presentato a: 57th Annual Meeting of the American-Society-of-Hematology - DEC 05-08, 2015, Orlando, FL [10.1182/blood.V126.23.1597.1597].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/410615
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
Social impact